by Jordana Choucair | Nov 5, 2021 | Life Sciences
The U.S. canceled a $600 million deal with Emergent BioSolutions, the vaccine manufacturer that ruined millions of Johnson & Johnson COVID-19 doses. The cancellation comes after Emergent’s manufacturing facilities in Baltimore were found to have produced millions...
by Jordana Choucair | Nov 5, 2021 | Life Sciences
Pfizer announced that its antiviral COVID-19 pill cut the risk of hospitalizations and deaths by 89 percent compared to those who received a placebo. The pharmaceutical company reported that three of the 389 people who received the drug (0.8 percent) were hospitalized...
by Jordana Choucair | Nov 4, 2021 | Life Sciences
Moderna Inc. scaled back the number of COVID-19 vaccines it plans to deliver this year from 1 billion shots to between 700 million and 800 million doses. The drugmaker said that longer delivery lead times for exports and a temporary impact from expanding its...
by Jordana Choucair | Nov 4, 2021 | Life Sciences
U.K. regulators authorized Merck & Co.’s COVID-19 antiviral pill molnupiravir, making it first in the world to clear the treatment. The FDA is still reviewing the drug, though the federal government made an advance purchase of 1.7 million courses of the...
by Jordana Choucair | Nov 3, 2021 | Life Sciences
CDC Director Dr. Rochelle Walensky endorsed a recommendation for vaccinating children ages 5-11 against COVID-19. The endorsement came after a group of CDC advisers voted 14-0 t to recommend Pfizer’s COVID-19 vaccine for children. During the approval process,...
by Jordana Choucair | Nov 2, 2021 | Life Sciences
Eli Lilly and Co. announced that the U.S. government bought 614,000 additional doses of its COVID-19 antibody therapy for $1.29 billion. As part of the agreement, Lilly will supply a minimum of 400,000 doses of bamlanivimab with etesevimab no later than December 31,...
Recent Comments